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Abstract
Dural vein thrombosis is an important but rare cause of headache. Therapy with cyclosporine has
been reported to result in thrombotic events. We report an unusual case of superior sagittal and
transverse sinus thrombosis associated with cyclosporine therapy in a kidney transplant patient.
Introduction
Dural vein thrombosis is an important but rare cause of
headache. It is associated with a wide range of conditions.
Therapy with cyclosporine has been reported to result in
thrombotic events. We report an unusual case of superior
sagittal and transverse sinus thrombosis associated with
cyclosporine therapy in a kidney transplant patient.
Case presentation
A 25-year-old Sri Lankan Sinhalese male post kidney
transplant patient presented with frontal headache of
insidious onset which worsened over 3 days, associated
with vomiting and fever. Neurological examination was
normal on admission, and over the next 12 hours he
developed weakness of the left side of the body, and soon
afterwards developed a left sided focal seizure with sec-
ondary generalization. There had been no previous epi-
sodes of similar headaches or seizures. He had had
membrano-proliferative glomeulonephritis progressing
to end-stage renal failure necessitating a live-related-
donor kidney transplant 11 months ago, and had been
well post transplant. He had been on immunosuppressive
therapy post- transplant: prednisolone, and cyclosporine
200 mg twice daily for the first 5 months post transplant,
later reduced to 200 mg mane and 100 mg nocte, which
was the dose on admission. He had also developed diabe-
tes 8 months ago, likely to be steroid induced. He had no
past history of rheumatological or autoimmune disorder,
and had had no previous episodes of venous or arterial
thrombosis.
He had no features of cyclosporine toxicity such as trem-
ors, hirsutism, or gum hyperplasia. Examination after the
seizure showed increased reflexes, increased tone and
reduced motor power to grade 4/5 on the left upper and
lower limbs. Bilateral papilloedema was present. Cardio-
vascular and respiratory system examination was normal,
and his blood pressure was normal throughout.
Full blood count showed a relative lymphocytosis and
mild thrombocytopenia. His blood picture showed no
evidence of microangiopathic haemolytic anaemia, and
coagulation profile was normal. Cytomegalovirus studies
(CMV PCR, CMV antigen test, CMV IgM antibodies) were
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analysis was clear, with no proteinuria. Serum albumin
levels were normal. Cyclosporine levels (trough) were
within therapeutic range. Cerebrospinal fluid examina-
tion, including gram stain and AFB smears, done on day 1
was normal; PCR for tuberculosis, and fungal and viral
studies were negative, and CSF bacterial and fungal cul-
tures showed no growth. A non-contrast-enhanced CT
scan of the head was performed (Figure 1A); no signs of
cerebral infarction or hemorrhage were seen, however cer-
ebral oedema was present. The 'dense triangle sign' was
observed, with hyper-intensity of the straight sinus, sug-
gestive of superior sagittal sinus thrombosis. Contrast-
enhanced CT scan of the head (Figure 1B) showed the
classical sign of superior sagittal sinus thrombosis,
namely the 'empty delta sign'. MRI brain confirmed the
diagnosis (Figure 2A), and also revealed thrombosis of the
right transverse sinus with a venous infarct of the right
parieto-occipital region (Figure 2B). Haematological and
biochemical screen for a prothrombotic tendency was
normal.
The patient's cyclosporine dose was reduced from 300 mg
to 200 mg daily. Prednisolone was continued without
dose modification. Anticoagulation was commenced with
low-molecular-weight-heparin and continued with warfa-
rin. Our patient's neurological symptoms and signs recov-
ered completely, and he was discharged for routine clinic
follow-up
Discussion
Dural venous thrombosis is an uncommon condition,
and the hospital frequency of dural venous thrombosis is
around 3-8 per 100000 population [1-3]. It is commoner
in women [3], and affects younger individuals [2,3], com-
pared with arterial infarcts which more commonly occur
in older patients. The superior sagittal sinus is the com-
monest site [4], and partial thrombosis may account for
up to 50% of these cases. Clinical presentations fall into
four patterns; pseudotumour syndrome, cerebral infarc-
tion, haemorrhage or venous hypertension [1]. Headache
is the commonest clinical feature, and is seen in around
90% of cases [1,4]. Focal neurological defects and
impaired level of consciousness are seen in around 50%
of patients; papilloedema and seizures also occur. Many
A. Non contrast enhanced CT scan showing the dense delta sign (thick arrow), with hyperintensity of the sagittal sinus (thin arrow)Figure 1
A. Non contrast enhanced CT scan showing the dense delta sign (thick arrow), with hyperintensity of the sag-
ittal sinus (thin arrow). B. Contrast enhanced CT scan showing the empty delta sign (thick arrow).Page 2 of 4
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tologic disorder (antiphospholipid antibody syndrome,
homocysteinuria, Factor V Leiden, protein C deficiency,
paroxysmal nocturnal haemoglobinuria, essential throm-
bocythaemia, thrombrotic thrombocytopenic purpura),
vasculitic disorders, sepsis (meningo-encephalitis, mas-
toiditis), trauma, severe dehydration, and certain drugs.
Pregnancy, or the use of oral contraceptive drugs may be
responsible in women. An aetiology is not identified in
around 13% of patients [4].
CT scan of the head demonstrates dural venous thrombo-
sis in about two thirds of cases [5], and is normal in the
rest. In a non-contrast CT, the dense triangle sign is seen,
i.e., hyperdensity with a triangular or round shape in the
posterior part of the superior sagittal sinus caused by the
venous thrombus [5,6]. On contrast-enhanced CT, the
characteristic 'empty delta' sign is seen as a triangular pat-
tern of contrast enhancement surrounding a central
region without enhancement formed by the thrombus
[7,8]. Indirect signs of thrombosis are frequently found-
these include intense contrast enhancement of falx and
tentorium, dilated transcerebral veins, small ventricles,
and parenchymal abnormalities [5-8].
The thrombosed sinus may be difficult to identify on MRI
scan during the acute stage of thrombosis, when the clot
tends to be iso-intense with brain on T1-weighted images
and hypo intense on T2-weighted images where it mimics
a flow void. From 3 to 7 days after thrombosis, the clot
becomes hyper intense on both T1- and T2-weighted
images and is thus easier to identify [9]. The MRI was
done on day 7 in our patient, and the clot is hypertense
(Figure 2A).
Cyclosporine is known to increase the risk of thrombosis.
The mechanism of this is complex. Cyclosporine increases
platelet aggregation, and aggregability increases at higher
cyclosporine levels [10,11]. Platelet thromboxane A2
release is also increased by cyclosporine, although there is
conflicting evidence as to whether this is related to blood
levels. The coagulation system is also affected by
cyclosporine, and some of these changes favor thrombosis
(elevated plasma fibrinogen levels, increased plasma vis-
cosity). Cyclosporine is also known to result in haemo-
lytic uraemic syndrome-thrombotic thrombocytopenic
purpura (HUS-TTP) in transplant patients [12], and TTP
can also result in thrombosis. Cyclosporine induced HUS-
TTP in renal transplant patients is different from classical
HUS-TTP. Thrombocytopenia and micro-angiopathic
haemolytic anaemia, which are the essential diagnostic
criteria in classical HUS-TTP, may be absent in
cyclosporine induced HUS-TTP, and acute renal failure is
the principal manifestation [13,14]. Sinus venous throm-
A. T1 weighted MRI - The superior sagittal sinus shows a hyper-intense signal of the thrombus seen in place of low-signal flow-ing bloodFi ure 2
A. T1 weighted MRI - The superior sagittal sinus shows a hyper-intense signal of the thrombus seen in place of 
low-signal flowing blood. B. T2 weighted MRI showing venous infarct in right parieto-occipital region.Page 3 of 4
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bosis has been reported in patients after bone marrow
transplantation who were on cyclosporine, although TTP
was not demonstrated in these patients [15]. Although
mild thrombocytopenia was present, our patient had no
evidence of microangiopathic haemolytic anaemia, nor
was there any evidence of renal involvement resulting
from micro-angiopathy, and cyclosporine induced HUS-
TTP was hence unlikely.
Dural sinus thrombosis due to meningo-encephalitis pre-
disposed to by immunosuppression was considered
unlikely, as the cerebrospinal fluid examination was nor-
mal. No other coagulopathy could be identified.
Although glomerulonephritis with proteinuria increases
the risk of thrombosis, our patient had a stable function-
ing kidney transplant for many months, and had no pro-
teinuria. Hypercoagulability associated with nephrotic
syndrome was therefore not likely. Cyclosporine induced
thrombosis, through a direct thrombotic effect, was the
most likely cause for our patients thrombosis. In our
patient, this took place with cyclosporine levels within
therapeutic range. Anticoagulation with heparin is the
most widely used treatment for dural vein thrombosis[4],
and has been shown to be beneficial [16,17], although a
meta-analysis failed to show statistical significance [18].
The overall prognosis for dural vein thrombosis is good
[4], with complete recovery in 57%. The mortality is
around 8%. This is the first report in the literature of dural
sinus thrombosis caused by cyclosporine in a renal trans-
plant patient.
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